OncoMatch/Clinical Trials/NCT05193188
A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
Is NCT05193188 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Anlotinib hydrochloride and PD-1 inhibitor for chondrosarcoma.
Treatment: Anlotinib hydrochloride · PD-1 inhibitor — There is no standard treatment for chondrosarcoma. Some small sample of studies has shown that anti-angiogenic TKIs show certain activity in the treatment of chondrosarcoma. PD-1 inhibitors, in recent years, have also been used in clinical practice and showed good efficacy. We intend to explore the response of chondrosarcoma to PD-1 monoclonal antibody and the influence of different IDH genotypes on PD-1 monoclonal antibody response.
Check if I qualifyExtracted eligibility criteria
Disease stage
Grade: iiiii
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-CTLA-4 therapy
Received anti-CTLA-4/PD-1/PD-L1 antibody treatment previously
Cannot have received: anti-PD-1 therapy
Received anti-CTLA-4/PD-1/PD-L1 antibody treatment previously
Cannot have received: anti-PD-L1 therapy
Received anti-CTLA-4/PD-1/PD-L1 antibody treatment previously
Cannot have received: anti-angiogenic TKI (anlotinib, apatinib, regorafenib)
Received anti-angiogenic TKI drugs (such as Anlotinib, Apatinib, Regofenib, etc.)
Cannot have received: anti-angiogenic antibody (bevacizumab)
anti-angiogenic antibody drugs (such as Bevacizumab)
Lab requirements
Blood counts
Hemoglobin ≥90g/L; ANC ≥1.5×10^9/L; Platelets ≥100×10^9/L
Kidney function
Serum creatinine ≤1.5×ULN or creatinine clearance (CCr) ≥60ml/min; urine protein <2+, 24h urine protein ≤1g
Liver function
Total bilirubin (TBIL) ≤1.5×ULN; ALT and AST ≤2.5×ULN, if liver metastasis ≤5×ULN
Cardiac function
LVEF ≥ lower limit of normal value (60%)
The main organs are functioning normally and meet the following criteria within 7 days before treatment: ... see full text for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify